
Metropolitan Police charge ITH Pharma over IV feed-linked baby deaths
pharmafile | October 31, 2018 | News story | Research and Development | ITH Pharma, Metropolitan Police, NHS, pharma
An investigation into the deaths and illnesses of several babies at a number of UK hospitals has prompted London’s Metropolitan Police to levy charges against ITH Pharma for its alleged role in the fatalities.
The police force accused the firm of causing the deaths of three babies and the illness of another four as a result of supplying a medical product which did not accurately represent its prescription, in nature and in quality, as well as of not taking adequate steps to ensure patients were not infected by contaminants.
The accusations have been made in relation to the investigation of a case which originated in September 2014, after the death in June of a baby at Guy’s and St Thomas’ hospital in London. This was followed by the death of another baby at the same hospital, and another at the Rosie Maternity Hospital in Cambridge. Three other hospitals in Luton and Stevenage were also affected.
The deaths coincided with a bacterial infection outbreak which affected babies receiving Total Parental Nutrition (TPN). All of the seven affected babies received TPN, but only one of the deaths was linked to the intravenous feed.
ITH Pharma has manufactured over 1.4 million components of TPN since its launch, and acted as the sole supplier of reactive feeding solutions to the NHS.
The company defended itself against the allegations, remarking: “As founders of ITH we have every sympathy for all the families affected, regardless of the cause. However, we are disappointed by the decision to charge the company and will vigorously defend this case.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

Five Facts about NHS and primary care
1 Primary care is the front door to the NHS, but it extends well beyond …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






